TNF receptors predict hip fracture risk in the WHI study and fatty acid intake does not modify this association

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 9, 2015, Pages 3380-3387

  Ing, Steven W ^a   Orchard, Tonya S ^a   Lu, Bo ^a   La Monte, Michael J ^b   Barbour, Kamil E ^c   Cauley, Jane A ^d   Jackson, Rebecca D ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; OMEGA 3 FATTY ACID;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CASE CONTROL STUDY; CAUCASIAN; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DRUG USE; FAT INTAKE; FEMALE; FOOD FREQUENCY QUESTIONNAIRE; FRAX SCORE; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MUSCULOSKELETAL DISEASE ASSESSMENT; OBSERVATIONAL STUDY; PHYSICAL ACTIVITY; POSTMENOPAUSE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SMOKING; BLOOD; DIET; HEALTH SURVEY; HIP FRACTURES; INCIDENCE; MIDDLE AGED;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; DIET; FATTY ACIDS, OMEGA-3; FEMALE; HEALTH SURVEYS; HIP FRACTURES; HUMANS; INCIDENCE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84941687235     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/JC.2015-1662     Document Type: Article

References (33)

1. Cauley JA. Public health impact of osteoporosis. J Gerontol A Biol Sci Med Sci. 2013;68:1243-1251.
2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007; 22:465-475.
3. Magaziner J, Fredman L, Hawkes W, et al. Changes in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling aged. Am J Epidemiol. 2003;157: 1023-1031.
4. Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int. 2009;20:1633-1650.
5. Haentjens P, Magaziner J, Colón-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Int Med. 2010;152:380-390.
6. Nanes MS. Tumor necrosis factor-β: molecular and cellular mechanisms in skeletal pathology. Gene. 2003;321:1-15.
7. Johnson RA, Boyce BF, Mundy GR, Roodman GD. Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice. Endocrinology. 1989; 124:1424-1427.
8. Kindle L, Rothe L, Kriss M, Osdoby P, Collin-Osdoby P. Human microvascular endothelial cell activation by IL-1 and TNF-α stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts. J Bone Miner Res. 2006;21:193-206.
9. Cauley JA, DanielsonME,BoudreauRM,et al. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res. 2007;22: 1088-1095.
10. Aderka D, Engelmann H, Shemer-Avni Y, et al. Variation in serum levels of the solubleTNFreceptors among healthy individuals. Lymphokine Cytokine Res. 1992;11:157-159.
11. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev. 1996;7:231-240.
12. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA. 1992;89:4845-4849.
13. Barbour KE, Boudreau R, Danielson ME, et al. Inflammatory markers and the risk of hip fracture: theWomen'sHealth Initiative. J Bone Miner Res. 2012;27:1167-1176.
14. Barbour KE, Lui LY, Ensrud KE, et al. Inflammatory markers and risk of hip fracture in older white women: the Study of Osteoporotic Fractures. J Bone Miner Res. 2014;29:2057-2064.
15. Orchard TS, Cauley JA, FrankGC,et al. Fatty acid consumption and risk of fracture in the Women's Health Initiative. Am J Clin Nutr. 2010;92:1452-1460.
16. Farina EK, Kiel DP, Roubenoff R, Schaefer EJ, Cupples LA, Tucker KL. Dietary intakes of arachidonic acid and α-linolenic acid are associated with reduced risk of hip fracture in older adults. J Nutr. 2011;141:1146-1153.
17. Orchard TS, Ing SW, Lu B, et al. The association of red blood cell n-3 and n-6 fatty acids with bone mineral density and hip fracture risk in the Women's Health Initiative. J Bone Miner Res. 2013;28: 505-515.
18. Trebble T, Arden NK, Stroud MA, et al. Inhibition of tumour necrosis factor-α and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation. Brit J Nutr. 2003;90: 405-412.
19. Zwart SR, Pierson D, Mehta S, Gonda S, Smith SM. Capacity of omega-3 fatty acids or eicosapentaenoic acid to counteract weightlessness-induced bone loss by inhibiting NF-κBactivation: from cells to bed rest to astronauts. J Bone Miner Res. 2010;25:1049-1057.
20. Huang JT, Welch JS, Ricote M, et al. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature. 1999;400:378-382.
21. Duque G. As a matter of fat: new perspectives on the understanding of age-related bone loss. Int Bone Miner Soc. 2007;4:129-140.
22. Deckelbaum RJ, Worgall TS, Seo T. n-3 Fatty acids and gene expression. Am J Clin Nutr. 2006;83(6 suppl):1520S-1525S.
23. Haag M, Magada ON, Claassen N, Böhmer LH, Kruger MC. Omega-3 fatty acids modulate ATPases involved in duodenal Ca absorption. Prostaglandins Leukot Essent Fatty Acids. 2003;68:423-429.
24. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials. 1998;19:61-109.
25. Curb JD, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003;13:S122-S128.
26. Anderson GL, Manson J, Wallace R, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol. 2003;13: S5-S17.
27. Robbins J, Aragaki AK, Kooperberg C, et al. Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA. 2007; 298:2389-2398.
28. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385-397.
29. Gold R, Michael YL, Whitlock EP, et al. Race/ethnicity, socioeconomic status, and lifetime morbidity burden in the Women's Health Initiative: a cross-sectional analysis. J Womens Health (Larchmt). 2006;15:1161-1173.
30. Woods NF, LaCroix AZ, Gray SL, et al. Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc. 2005;53:1321-1330.
31. Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann Epidemiol. 1999;9:178-187.
32. Schakel SF, Sievert YA, Buzzard IM. Sources of data for developing and maintaining a nutrient database. J Am Diet Assoc. 1988;88: 1268-1271.
33. Manson JE, Bassuk SS, Lee IM, et al. The VITaminDand OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitaminDand marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33:159-171.